Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00092157
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of two approved drugs in lowering high cholesterol when taken together, compared to taking only one of the drugs.
- Detailed Description
The duration of treatment is 12 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 571
Inclusion Criteria
- Elevated cholesterol level
Exclusion Criteria
- Liver disease
- Known allergies to study drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Fasting triglyceride levels at 12 weeks.
- Secondary Outcome Measures
Name Time Method Total Cholesterol, LDL-C, HDL-C, VLDL-C, VLDL-TG, Apo A-I, and Apo B, CRP, PAI-1, fibrinogen, fasting plasma glucose, and fasting insulin